Caerus Investment Advisors LLC Acquires New Holdings in United Therapeutics Corporation $UTHR

Caerus Investment Advisors LLC acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 1,464 shares of the biotechnology company’s stock, valued at approximately $713,000.

A number of other institutional investors also recently modified their holdings of UTHR. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Monday, June 8th. The shares were sold at an average price of $547.50, for a total transaction of $5,475,000.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,334,610. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,113,210.79. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 624,984 shares of company stock worth $352,682,302 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Trading Up 0.2%

Shares of UTHR stock opened at $545.40 on Friday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm’s fifty day simple moving average is $567.24 and its 200 day simple moving average is $521.17. The firm has a market capitalization of $23.15 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the firm posted $6.63 EPS. The company’s revenue was down 1.6% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. UBS Group lifted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Finally, Bank of America boosted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.